Fluidigm Announces New Integrated Fluidic Circuits for Single-Cell Genomics on the C1 System

South San Francisco, California, UNITED STATES

SOUTH SAN FRANCISCO, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced new integrated fluidic circuits (IFCs) that will increase the number of single cells that can be isolated and analyzed on the C1™ system. Bringing together the trusted Fluidigm® C1 single-cell isolation system with the benefits of a growing suite of optimized microfluidic circuits, researchers can confidently expand their single-cell studies while taking advantage of well-established, industry-proven workflows.

Single-cell research is fast becoming a technology standard in basic and translational research, biomarker discovery, and therapeutic development. Using single-cell approaches, researchers are visualizing biological systems with unprecedented resolution using RNA, DNA, epigenetic, and protein markers to uncover novel cellular subpopulations and networks that control human health and disease. Enabling the largest suite of integrated single-cell analysis workflows in the industry, the C1 has been used by leading research institutions around the world to advance immunology, cancer, neuroscience, and stem cell research.

“We are very pleased to announce the release of new medium-cell (10–17 µm) IFCs designed to capture up to 96 cells with higher single-cell capture efficiency. These new IFCs have been extensively tested both internally and at customer sites, demonstrating significantly improved single-cell capture performance. We plan to initiate customer shipments by the end of this month and are confident our customers will be very pleased with their performance,” said Gajus Worthington, CEO of Fluidigm. “Supporting our continued commitment to provide a wide range of high-quality workflows for single-cell characterization, we also plan to release two new high‑throughput IFCs on the C1 system this year to enable screening of larger cell populations at single‑cell resolution.”

High-quality workflows for medium-to-large-scale single-cell studies are essential to identifying rare cell populations. This has become especially important in the highly funded areas of immunology and cancer immunotherapy, where cell populations in the tumor microenvironment and in blood are composed of complex cellular networks comprising many different cell types and phenotypic states.

Designed to capture up to 800 small (5–10 µm) or medium (10–17 µm) cells on the C1, new high-throughput IFCs will enable scientists to profile larger cell populations using the same high-quality Fluidigm workflow that has become an industry standard. We have accelerated the development of a new small-cell high-throughput IFC based on increased customer demand, now planned for release in early Q3. This new IFC incorporates the same high-performing design features as the current small-cell IFC, which has become a mainstay in immunology studies. In early Q4, we plan to release a new medium‑cell high-throughput IFC that incorporates the same design optimizations as the new medium‑cell IFC for use with a diverse array of cell types, including cancer cells.

“We continue to be amazed by the great discoveries Fluidigm single-cell technologies have helped enable,” said Worthington. “Together with our customers, we will eagerly pursue new insights made accessible by these products.”

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the anticipated availability and performance of new Fluidigm IFCs and Fluidigm’s plans, objectives, expectations, and strategies relating to these new IFCs. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the potential for delays in the timing of new product releases; the potential for product performance or quality issues in new products and risks associated with Fluidigm’s ability to address such issues; intellectual property risks; competition; Fluidigm’s research and development, sales, marketing, and distribution plans and capabilities; reduction in research and development spending or changes in budget priorities by customers; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Fluidigm’s business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2015, and in its other filings with the Securities and Exchange Commission. Additional information will also be set forth in Fluidigm’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 to be filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements except as may be required by law.

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multi-parameter mass cytometry technology, and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

We use our website (www.fluidigm.com), corporate Twitter account (@Fluidigm), Facebook page (https://www.facebook.com/Fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

For more information, please visit www.fluidigm.com.

Fluidigm, the Fluidigm logo, and C1 are trademarks or registered trademarks of Fluidigm Corporation.


Contact Data